Abstract 407P
Background
Tumor mutation burden (TMB) served as an effective biomarker predicting efficacy of mono-immunotherapy for non-small cell lung cancer (NSCLC). While, establishing a precise TMB predicting model is essential to monitor which populations are likely to respond to immunotherapy or prognosis and to maximize the benefits of treatment.
Methods
Available Formalin-fixed paraffin embedded tumor tissues were collected from 499 patients with NSCLC. Targeted sequencing of 636 cancer related genes were performed and TMB was calculated.
Results
Distribution of TMB was significantly (p < 0.001) correlated with sex, clinical features (pathological /histological subtype, pathological stage, lymph node metastasis and lympho-vascular invasion). It was also significantly (p < 0.001) associated with mutations in genes like TP53, EGFR, PIK3CA, KRAS, EPHA3, TSHZ3, FAT3, NAV3, KEAP1, NFE2L2, PTPRD, LRRK2, STK11, NF1, KMT2D and GRIN2A. No significant correlations were found between TMB and age, neuro-invasion (p=0.125), and tumor location (p= 0.696). Patients with KRAS p.G12 mutations and FAT3 missense mutations were associated (p< 0.001) with TMB. TP53 mutations also influence TMB distribution (P<0.001). TMB is reversely related to EGFR mutations (P<0.001) but is not differed by mutation types. According to multivariate logistic regression model, genomic parameters can effectively construct model predicting TMB, which may be improved by introducing clinical information.
Conclusions
Our study demonstrates genomic together with clinical features yielded a better reliable model predicting TMB-high status. A simplified model consisting of less than 20 genes and couples of clinical parameters sought to be useful to provide TMB status with less cost and waiting time.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
D. Shao: Full/Part-time employment: BGI Genomics. All other authors have declared no conflicts of interest.
Resources from the same session
413P - South Korean real-world treatment patterns in patients with EGFRm NSCLC
Presenter: Jae Cheol Lee
Session: e-Poster Display Session
414P - Incidence and characteristics of lung cancer diagnosed after kidney transplantation at the National Kidney and Transplant Institute
Presenter: Adeline Gonzales
Session: e-Poster Display Session
415P - Real-world fusion landscape of RET gene fusions and its response to cabozantinib in Chinese non-small cell lung cancer (NSCLC) using next generation sequencing
Presenter: Chunwei Xu
Session: e-Poster Display Session
416P - A single institute study evaluating the additional benefit of blood NGS testing over conventional molecular testing in metastatic adenocarcinoma lung
Presenter: Rajashree Ashwath
Session: e-Poster Display Session
417P - Efficacy and safety of lorlatinib in subsequent lines of therapy in ALK and ROS1 positive lung cancer
Presenter: Amit Kumar
Session: e-Poster Display Session
418P - All EGFR mutations are (not) created equal: Focus on uncommon EGFR mutations
Presenter: Ullas Batra
Session: e-Poster Display Session
419P - Surgical treatment of malignant tumours and metastatic lesions of the chest wall
Presenter: Zhanat Pyssanova
Session: e-Poster Display Session
421P - A multicenter, randomized, double-blind, placebo (PBO)-controlled, phase III trial of lenvatinib (LEN) in patients (pts) with radioiodine-refractory differentiated thyroid cancer (RR-DTC) in China
Presenter: Ming Gao
Session: e-Poster Display Session
422P - Response rate and time to progression after first line chemotherapy with cisplatin and adriamycin in patients with metastatic osteosarcoma at presentation
Presenter: Sivasubramaniam Kumaravelu
Session: e-Poster Display Session
423P - Positive lymph node and thicker Breslow are associated with poor prognosis of high-risk resected melanomas
Presenter: Roby Cahyono
Session: e-Poster Display Session